Barrow BA - Search Results

1

Evaluation of serum 1,5 anhydroglucitol levels as a clinical test to differentiate subtypes of diabetes.

Pal A, Farmer AJ, Dudley C, Selwood MP, Barrow BA, Klyne R, Grew JP, McCarthy MI, Gloyn AL, Owen KR. Pal A, et al. Among authors: barrow ba. Diabetes Care. 2010 Feb;33(2):252-7. doi: 10.2337/dc09-1246. Epub 2009 Nov 23. Diabetes Care. 2010. PMID: 19933992 Free PMC article.

2

Perceptions of heart attack risk amongst individuals with diabetes.

Price HC, Dudley C, Barrow B, Griffin SJ, Holman RR. Price HC, et al. Prim Care Diabetes. 2009 Nov;3(4):239-44. doi: 10.1016/j.pcd.2009.09.005. Epub 2009 Nov 5. Prim Care Diabetes. 2009. PMID: 19896425

3

Identification of a novel beta-cell glucokinase (GCK) promoter mutation (-71G>C) that modulates GCK gene expression through loss of allele-specific Sp1 binding causing mild fasting hyperglycemia in humans.

Gasperíková D, Tribble ND, Staník J, Hucková M, Misovicová N, van de Bunt M, Valentínová L, Barrow BA, Barák L, Dobránsky R, Bereczková E, Michálek J, Wicks K, Colclough K, Knight JC, Ellard S, Klimes I, Gloyn AL. Gasperíková D, et al. Among authors: barrow ba. Diabetes. 2009 Aug;58(8):1929-35. doi: 10.2337/db09-0070. Epub 2009 May 1. Diabetes. 2009. PMID: 19411616 Free PMC article.

4

Three-year efficacy of complex insulin regimens in type 2 diabetes.

Holman RR, Farmer AJ, Davies MJ, Levy JC, Darbyshire JL, Keenan JF, Paul SK; 4-T Study Group. Holman RR, et al. N Engl J Med. 2009 Oct 29;361(18):1736-47. doi: 10.1056/NEJMoa0905479. Epub 2009 Oct 22. N Engl J Med. 2009. PMID: 19850703 Free article. Clinical Trial.

5

Use of focus groups to develop methods to communicate cardiovascular disease risk and potential for risk reduction to people with type 2 diabetes.

Price HC, Dudley C, Barrow B, Kennedy I, Griffin SJ, Holman RR. Price HC, et al. Fam Pract. 2009 Oct;26(5):351-8. doi: 10.1093/fampra/cmp041. Epub 2009 Jun 21. Fam Pract. 2009. PMID: 19546119

6

Availability of type II diabetic families for detection of diabetes susceptibility genes.

Cook JT, Page RC, O'Rahilly S, Levy J, Holman R, Barrow B, Hattersley AT, Shaw AG, Wainscoat JS, Turner RC. Cook JT, et al. Diabetes. 1993 Oct;42(10):1536-43. doi: 10.2337/diab.42.10.1536. Diabetes. 1993. PMID: 8375595

7

Linkage analysis of glucokinase gene with NIDDM in Caucasian pedigrees.

Cook JT, Hattersley AT, Christopher P, Bown E, Barrow B, Patel P, Shaw JA, Cookson WO, Permutt MA, Turner RC. Cook JT, et al. Diabetes. 1992 Nov;41(11):1496-500. doi: 10.2337/diab.41.11.1496. Diabetes. 1992. PMID: 1397724

8

Changes in amylin and amylin-like peptide concentrations and beta-cell function in response to sulfonylurea or insulin therapy in NIDDM.

Rachman J, Payne MJ, Levy JC, Barrow BA, Holman RR, Turner RC. Rachman J, et al. Among authors: barrow ba. Diabetes Care. 1998 May;21(5):810-6. doi: 10.2337/diacare.21.5.810. Diabetes Care. 1998. PMID: 9589246 Clinical Trial.

9

Relative hyperproinsulinemia of NIDDM persists despite the reduction of hyperglycemia with insulin or sulfonylurea therapy.

Rachman J, Levy JC, Barrow BA, Manley SE, Turner RC. Rachman J, et al. Among authors: barrow ba. Diabetes. 1997 Oct;46(10):1557-62. doi: 10.2337/diacare.46.10.1557. Diabetes. 1997. PMID: 9313749 Clinical Trial.

10

Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM.

Rachman J, Gribble FM, Barrow BA, Levy JC, Buchanan KD, Turner RC. Rachman J, et al. Among authors: barrow ba. Diabetes. 1996 Nov;45(11):1524-30. doi: 10.2337/diab.45.11.1524. Diabetes. 1996. PMID: 8866556

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

18 results

Search Page